[Modelling of the adeno-herpetic infection in lymphoblastoid cell cultures].

Viral infections take the key place in medical practice. A large group of diseases are caused by adenoviral and herpes infection. As a rule, the investigations carried out in scientific laboratories are directed to the study of certain aspects of the interaction between the virus and the cell on the model of single infection. At the same time different viral infections at the level of macroorganism are constantly interacting with each other. The paper presents the studies on the selection of optimal models of lymphoblastoid cell lines for analysis of peculiarities of the mixed adeno-herpetic infection. The reproduction of human adenovirus type 5 and Epstein-Barr virus in the mono- and mixed infection in lymphoblastoid cell cultures of B-phenotype: B95-8, Raji, Namalwa have been studied. Both interfering and inhibiting action of viruses are shown. So EBV, which has a short 48-hour cycle of reproduction, inhibits the adenovirus at the given time. The obtained cell models of adeno-herpes infection will allow to study peculiarities of the antiviral action of etiotropic antiviral preparations in conditions of coinfection.

[AntiEBV activity of 6-azacytidine and its derivatives].

Epstein-Barr virus (EBV) causes several lymphoproliferative diseases, lesions of the central and peripheral nervous systems. Spectrum of etiotropic medicines against EBV is limited. The paper presents the anti-virus research of modified nucleoside with a wide spectrum of action - 6-azacytidine and its derivatives (2'-3'-seco-5-methyl-6-AC, 2',3'-dideoxy-2',3'-didehydro-6-AC and 2'-deoxy-6-AC) on the model of Epstein-Barr virus in Raji lymphoblastoid cells. Parameters of cytotoxicity (CC,) for the investigated substances were determined which amounted to 120 microg/ml, 180 microg/ml, 500 microg/ml, 330 microg/ml, and the effective concentration (ECU)--0.5 microg/ml. 1 microg/ml, 4 microg/ml, 11 microg/ml, in accordance with the sequence of preparations listed above. The results indicate a high antiEBV activity since their selectivity indexes (SI) were 240, 180, 125, 30 that is 1.3-10 times higher than the reference substance acycloguanosine. Apoptosis-stimulating action of 6-azacytidine and its derivatives was revealed. An increase of percentage of apoptotic cells in EBV-infected Raji cells and those treated with investigated substances as compared to uninfected ones was observed after 24 hours. Thus, our results provide new biological properties of the azacytidine substances.

[Effect of proteflazid on the Epschtein-Barr virus].

Cytotoxicity and anti-EBV activity ofProteflasid (SPC Ekopharm, Kyiv) in two solvents: propylene glycol (PG) and syrup--in the culture of lymphoblastoid Raji cells were studied. It was determined that cytotoxic concentration (CC50) of Proteflasid in propylene glycol was 40 microg/ml, and in syrup--150 microg/ ml; effective concentration (EC50) of Proteflasid was equal for both solvents and was 0.1 microg/ml (under therapeutic action of Proteflasid) and 0.5 microg/ml (under prophylactic action of Proteflasid). Selectivity index (SI) ofProteflasid in PG was 400 and 80 (for therapeutic and prophylactic scheme, accordingly), 1500 and 300 (for therapeutic and prophylactic scheme, accordingly) in syrup.

[Specific immunoglobulins as effective drugs for treatment of virus infections: present state and urgent tasks in Ukraine]. / Spetsificheskie immunoglobuliny kak éffektivnye preparaty dlia lecheniia virusnykh infekstii: sovremennoe sostoianie i nasushchnye zadachi dlia Ukrainy.

The thesis about importance of specific immunoglobulin preparations in treatment of infectious diseases of viral and microbial etiology, uncontrollable infections, caused by representatives of herpes viruses family in particular, is developed in the paper. The types of immunoglobulin preparations, their advantages, technology peculiarities has been considered; the experience of application, including that of the authors have been analyzed. The necessity and expedience of intensive development of this branch of immunobiotechnology in Ukraine is proved, especially in connection with a high level of infectious morbidity in this country, concrete recommendations are given.